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Abstract
OBJECTIVE: The objective of this selective EBM review is to
determine whether or not Flibanserin is a safe and effective
treatment to increase sexual desire in premenopausal women with
Hypoactive Sexual Desire Disorder.
STUDY DESIGN: Review of three randomized controlled trials
published in 2013, 2012, and 2012; selection was based on their
relevance to the clinical question and if they contained patient
oriented outcomes.
DATA SOURCES: Three peer-reviewed randomized controlled trials
comparing the use of Flibanserin to placebo in the treatment of
Hypoactive Sexual Desire Disorder were found on PubMed.
OUTCOME(S) MEASURED: For each trial patients were divided into
two groups and assigned to either Flibanserin treatment or
placebo treatment. Each trial assessed number of satisfying
sexual events (SSE), Patient Global Impression of Improvement
(PGI-I), and Adverse Events (AEs), events leading to the
discontinuation of the trial.
RESULTS: All three trials showed a statistically significant
(p<.05) increase in mean change from baseline for number of
satisfying sexual events when compared to the mean change from
baseline of the placebo group. Thorp et al. and DeRogatis et al.
both had PGI-I data that expressed the NNT of 6, while Katz et
al. showed a NNT of 8. Thorp et al. reported adverse events that
showed a NNH of 31, DeRogatis et al. reported adverse events
that showed NNH of 12, and Katz et al. reported adverse events
that showed NNH of 16.
CONCLUSIONS: Based on all three trials, there is a statistically
significant increase in sexual desire with the use of
Flibanserin compared to the use of placebo in premenopausal
women with HSDD. The analysis of PGI-I showed a moderately low
NNT indicating that the drug, Flibanserin, was effective in
improving the women’s condition. The analysis of AEs showed a
moderate numbers needed to harm indicating that there are risks
to taking Flibanserin. All serious safety concerns were
investigated and deemed not related to the use of Flibanserin.
Flibanserin is a relatively safe drug, and is an effective
treatment of HSDD symptoms in premenopausal women.
KEY WORDS: Flibanserin
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Introduction:
Hypoactive Sexual Desire Disorder is a sexual disorder
characterized by low sexual desire that causes marked distress
or interpersonal difficulty.1 Sexual dysfunction is a very common
problem for both men and women, but treatment options for women
are disproportionately fewer than they are for men. Historically
female sexual dysfunction has been believed to be heavily
psychopathologic, while male sexual dysfunction has been viewed
as more physiologic. In addition, the topic of sex is culturally
taboo to discuss; especially for women in America. Each of these
factors may contribute to the disproportion of treatment options
for women with sexual dysfunction. This paper assess three
double-blind, randomized, controlled trials testing the efficacy
and safety of the use of Flibanserin to increase sexual desire
in premenopausal women with Hypoactive Sexual Desire Disorder.
Throughout the process of the analysis of these randomized
control trials, Flibanserin has moved on from trial phase and is
now available to the public. Flibanserin is the first and only
pharmacotherapy option being offered for the treatment of HSDD.
HSDD effects up to 14% of premenopausal women, and is the
most commonly reported type of sexual dysfunction.2 The total
impact that HSDD has on healthcare cost is unknown, but women
with a diagnosis of HSDD have a total annual healthcare
expenditure that is 16.8% higher than women without HSDD.3 This

Lee, Flibanserin and HSDD, 2

is due to the fact that women with HSDD tend to have on average
two more medical office visits per year than women without HSDD.3
The exact etiology of HSDD is unknown, but it is thought to
be multifactorial. Possible contributing factors include,
decreased testosterone or estrogen levels, psychological
factors, and sociological factors such as relationship conflict.4
Prior to Flibanserin there were no pharmacotheraputics for
the treatment of HSDD. Often patients with HSDD see a counselor
or a sex therapist to help with psychological factors
contributing to the disease. Other treatments consist of herbal
remedies. The top herbal remedies are Provestra, Femestril, and
Vigorelle.4 Even though there are multiple options available for
the treatment of HSDD, there is no current treatment that is
effective in all patients. For this reason there is a need for
more treatment options of HSDD. Therefore, determining the
safety and efficacy of Flibanserin is important.
Objective:
The objective of this selective EBM review is to determine
whether or not Flibanserin is a safe and effective treatment to
increase sexual desire in premenopausal women with Hypoactive
Sexual Desire Disorder.
Methods:
Three double blind, randomized controlled trials, were
included in this systematic review. Studies were selected based
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on various criteria including populations studied, interventions
used, comparisons made, and outcomes measured. In all three
studies, the populations being measured consisted of healthy
premenopausal women greater than or equal to the age of 18 with
a diagnosis of HSDD. The women in the study also had to be in a
stable, communicative, monogamous, heterosexual relationship of
> 1 year’s duration and had to have a sexually functional
partner. Each article measured the effects of 100mg of
Flibanserin taken orally once daily before bedtime and compared
it to the effects of taking a visually equivalent placebo pill
at bedtime. Each of the articles also measured desire and
improvement in libido by recording the following: number of
satisfying sexual events (SSE) and Patient’s Global Impression
of Improvement (PGI-I). Each article measured safety by
recording the number of Adverse Events (AE).
All three articles were researched via the PubMed database
and were selected based on relevance to the clinical question.
Each article was also selected on the basis that their measured
outcomes were patient oriented evidence that matters (POEMS).
The Key word entered in the PubMed search was “Flibanserin”.
All three of the selected studies were peer reviewed journal
articles written in the English language published between 2012
and 2013.
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The studies included in this systematic review were
selected based on the following inclusion criteria: all were
primary research studies (randomized controlled trials, cohort
studies, crossover studies, etc.), all were published after
1998, all included relevant POEMs, and all evaluated the safety
and efficacy of Flibanserin on Hypoactive Sexual Desire Disorder
as one of the measured outcomes. Exclusion criteria included
women under 18 years of age, women with sexual dysfunctions
other than HSDD; any other psychiatric disorder that could
impact sexual function; MDD within the previous 6 months; a
score of 14 on the Beck Depression Inventory-II; any ongoing
serious clinical disorder; or substance abuse in the past year.
Statistics reported included standard deviations, p-values, and
mean change from baseline. Table 1 below shows the demographics
and characteristics of the included studies.
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Table 1: Demographics and Characteristics of Included Studies
Study

Type

Begonia
(2013)
Violet
(2012)
Daisy
(2012)

RDBPC

# of
Pts
1090

RDBPC

585

RDBPC

794

Age

Inclusion

Exclusion

W/D

36.5
+/-8
35.5
+/- 7
35.4
+/- 7

Premenopausal women
>18 years old, with
diagnosis of HSDD. A
Female Sexual
Distress
ScaleRevised (FSDSR) score of at least
15, indicating
sexual distress, and
a Sexual Interest
and Desire
Inventory-Female
receptivity item
rating of 0 or 1,
indicating little or
no receptivity to
partner’s sexual
approach. Women had
to be in a stable,
communicative,
monogamous,
heterosexual
relationship of > 1
year’s duration and
to have a sexually
functional partner.

Sexual
dysfunctions
other than
HSDD, arousal
disorder, or
orgasm
disorder; any
other
psychiatric
disorder that
could impact
sexual
function; MDD
within the
previous 6
months; a score
of 14 on the
Beck Depression
Inventory-II;
any ongoing
serious
clinical
disorder; or
substance abuse
in the past
year.

233
152
255

Interventio
n
Flibanserin
100mg qhs
Flibanserin
100mg qhs
Flibanserin
100mg qhs

Outcomes Measured:
All three articles measured the number of satisfying sexual
events (SSE), Patient Global Impression of Improvement (PGI-I),
and Adverse Events (AEs). SSE was recorded by the subjects via
an eDiary. A sexual event was defined as sexual intercourse,
oral sex, masturbation, or genital stimulation by a partner.1,5,6
In order to measure sexual desire improvement each article used
PGI-I. PGI-I consisted of a single question, “How is your
condition today compared with when you started the study
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medication?” Subjects answered the question on a 1-7 scale 1
(very much improved), 4 (no change), and 7 (very much worse).
PGI was measured at weeks 4, 8, 16, and 24.1,5,6 To determine
safety of Flibanserin use, Adverse Events leading to the
discontinuation of the trial was measured throughout the
duration of the trial.
Results:
Three double-blind randomized controlled trials compared
the effects of 100 mg of Flibanserin with a visually equivalent
placebo pill on premenopausal women with HSDD. Thorp et al.
assigned 399 women to placebo and 396 women to the experimental
group. Of the 399 women in the placebo group, 111 discontinued
the trial; 43 due to adverse events and 68 due to various
reasons such as non-compliance or being lost to follow up. Of
the 395 women receiving Flibanserin, 144 discontinued; 62 due to
adverse events, and the remaining to other causes.5 Katz et al.
assigned 547 women to the placebo group and 543 women into the
Flibanserin group. Of the 547 women in the placebo group, 99
discontinued the trial, 20 due to adverse events and the
remainder for various reasons. Of the 543 women in the
Flibanserin group, 134 discontinued the trial, 53 due to adverse
events.1 DeRogatis et al. assigned 295 women into the placebo
group and 290 into the Flibanserin group. Of the 295 women in
the placebo group, 61 discontinued the trial; 10 due to adverse
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events. Of the 290 women in the Flibanserin group 91 women
discontinued, 33 due to adverse events.6 Graph 1, seen below,
illustrates withdrawal numbers in all three trials.

Subject withdrawls
600
500
400
300
200
100
0
Placebo
Begonia

Flibanserin
Begonia

Completed trial

Placebo
Daisy

Flibanserin
Daisy

Lost to follow up

Placebo
Violet

Flibanserin
Violet

Women with AEs

Graph 1: Subject withdrawals and completions.
All three trials showed a statistically significant (p<.05)
increase in mean change from baseline for number of satisfying
sexual events when compared to the mean change from baseline of
the placebo group. These results are illustrated in Table 2
below.
Table 2: Efficacy of Flibanserin in the treatment of Hyposexual
Desire Disorder using Satisfying Sexual Events.
Study

Placebo Mean change
from baseline (SD)

P value

Thorp et al.

Flibanserin 100 mg.
Mean change from
baseline (SD)
1.9 (.3)

1.1(.2)

<.01

DeRogatis et al.

1.6 (.23)

.8 (.2)

<.01

Katz et al.

2.5 (4.6)

1.5 (4.5)

<.001
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All three randomized control trials reported PGI-I scores
after the 24 weeks of the trial was over. Data from these trials
were reported as continuous data that was later converted into
dichotomous format to evaluate efficacy of treatment. Thorp et
al. reported PGI-Is that showed 47% of women who were taking
Flibanserin felt an improvement in their condition while 30.3%
of women taking placebo felt that their condition had improved;
that results in a NNT of 6.5 DeRogatis et al. reported PGI-Is
that showed 50% of women who were taking Flibanserin felt an
improvement in their condition while 30.3% of women taking
placebo felt that their condition had improved; that results in
a NNT of 6.6 A NNT of 6 means that if 6 people were treated with
Flibanserin, one person would benefit more than that of people
taking placebo. Katz et al. reported PGI-Is that showed 51.8% of
women who were taking Flibanserin felt an improvement in their
condition while 37.7% of women taking placebo felt that their
condition had improved; that results in a NNT of 8.1 The results
for PGI-I are illustrated in Table 3 seen below.
Table 3: Efficacy of Flibanserin in the treatment of Hyposexual
Desire Disorder using PGI-I.
Study
CER
EER
RBI
ABI
NNT
Thorp et al.
.303
.500
.650
.197
6
DeRogatis et al.

.303

.470

.55

.168

6

Katz et al.

.377

.518

.374

.141

8
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Adverse events data from all three trials was reported as
continuous data and was later converted into dichotomous format
to evaluate safety of treatment. Thorp et al. reported adverse
events in 13.4% of those taking Flibanserin and 10.1% of those
taking placebo, resulting in a NNH of 31.5 A NNH of 31 means that
it takes 31 people to be treated with Flibanserin before 1
adverse event happens that wouldn’t have otherwise happened
using the placebo. DeRogatis et al. reported adverse events in
11.4% of those taking Flibanserin and 3.4% of those taking
placebo, resulting in a NNH of 12.6 Katz et al. reported adverse
events in 9.6% of those taking Flibanserin and 3.7 % of those
taking placebo, resulting in a NNH of 16.1 The results of adverse
events are illustrated in Table 4 seen below. The most common
adverse effects reported in all three trials were somnolence,
dizziness, nausea, and fatigue.1,5,6 In all three cases, the
serious adverse events were deemed not related to the drug by
the investigator.
Table 4: Safety of Flibanserin in the treatment of Hyposexual
Desire Disorder using.
Study
CER
EER
RRI
ARI
NNH
Thorp et al.
.034
.114
2.35
.08
12.5→12
DeRogatis et al.

.101

.134

.327

.033

30.3→30

Katz et al.

.037

.096

1.59

.059

16.96 →16
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Discussion:
Using three double-blind RCT’s, this meta-analysis reviewed
the safety and efficacy of Flibanserin in improving the sexual
desire in premenopausal women ≥18 years old with HSDD. All three
trials showed that in premenopausal women with HSDD taking 100mg
of Flibanserin before bed was associated with a statistically
significant increase in sexual desire expressed by SSE. The
analysis of PGI-I showed a moderately low NNT indicating that
the drug, Flibanserin, was effective in improving the women’s
condition. The analysis of AEs showed a moderate numbers needed
to harm indicating that there are risks to taking Flibanserin.
All serious safety concerns were investigated and deemed not
related to the use of Flibanserin.
Conclusion:
Based on the three studies above, it can be concluded that
Flibanserin is effective at improving the condition and
increasing sexual desire in women in premenopausal women with
HSDD, but the risks and benefits must be weighed on an
individual basis. No serious or life threatening risks have been
identified as a result of the use of Flibanserin. Flibanserin is
a relatively safe drug and is an effective treatment of HSDD
symptoms in premenopausal women.
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